GlassScriptPhysician profile
Melissa Abreu
NPI 1427438506
$7,732.15
in general payments reported to CMS, 2019-2025
33 companies · $2,457 in 2025
The $2,457 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $1,071 · 2023: $1,732 · 2024: $1,796 · 2025: $2,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,886 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,885.83 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,278.53 | 2021-2025 | Airsupra, Farxiga, Fasenra |
| Abbvie INC. | $942.09 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Novo Nordisk INC | $548.83 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $503.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $397.71 | 2023-2025 | |
| Exact Sciences Corporation | $372.97 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $372.29 | 2024-2025 | Recorlev |
| Novartis Pharmaceuticals Corporation | $360.50 | 2021-2025 | |
| Corcept Therapeutics | $319.73 | 2023-2024 | Korlym |
| Astellas Pharma US INC | $295.91 | 2023-2024 | Veozah, Myrbetriq |
| Aimmune Therapeutics, INC. | $259.88 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $255.69 | 2024-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $223.35 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $184.07 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $167.45 | 2022-2023 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $165.45 | 2022-2025 | |
| Insulet Corporation | $164.64 | 2025 | Omnipod |
| Nestle Healthcare Nutrition INC. | $159.54 | 2021-2023 | |
| Lilly USA, LLC | $126.45 | 2023-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $106.28 | 2025 | Gemtesa |
| Amgen INC. | $104.45 | 2021-2025 | Repatha, Otezla, Otezla |
| Ironwood Pharmaceuticals, INC | $81.20 | 2021 | |
| Horizon Therapeutics Plc | $71.27 | 2021-2022 | |
| Amarin Pharma, INC. | $58.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.45 | 2022-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $34.28 | 2025 | Symbravo |
| Allergan, INC. | $25.00 | 2021 | |
| Nevro Corp. | $24.85 | 2021 | |
| Merck Sharp & Dohme LLC | $22.68 | 2025 | Capvaxive, Recombivax Hb, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.25 | 2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $18.78 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.35 | 2025 | Eliquis |
| Althera Pharmaceuticals LLC | $11.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Abreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.